Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Ohio Pen/10267303

Webcast scheduled for Monday, July 22 at 8:00 a.m. Eastern Time

CARLSBAD, Calif., July 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from the Phase 1/2a HALOS study of ION582 for the treatment of people with Angelman syndrome. Results from the HALOS study will also be presented on Wednesday, July 24 at the 2024 Angelman Syndrome Foundation (ASF) Family Conference and Research Symposium in Sandusky, Ohio.

The webcast may be accessed at A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter) and LinkedIn.

More on Ohio Pen
Ionis Pharmaceuticals Investor Contact:
D. Wade Walke, Ph.D. – [email protected] 760-603-2331

Ionis Pharmaceuticals Media Contact:
Hayley Soffer – [email protected] – 760-603-4679

SOURCE Ionis Pharmaceuticals, Inc.
Filed Under: Business

Show All News | Report Violation


Latest on Ohio Pen